Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Products > Novel inhibitors

Novel inhibitors

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DCC3741 Nsc127133
Novel inhibitor of the second bromodomain (BD2) of the BET family protein BRD2
More description
DCC3740 Nsc-126188
Apoptosis inducer; Antitumor agent
More description
DCC3739 Nsc-12404
Selective non-lipid agonist of LPA2/3
More description
DCC3738 Nsc-117199
Selective inhibitor of shp2 protein tyrosine phosphatase (PTP)
More description
DCC3737 Nsc114792
Novel selective inhibitor of JAK3
More description
DCC3736 Nsc109779
Novel potent inhibitor of Huntington's disease (HD) pathogenesis via targeting CAG repeats RNA and Poly Q protein
More description
DCC3735 Nsc109131
Inhibitor of human tyrosyl-DNA phosphodiesterase 1 (TDP1)
More description
DCC3734 Nsc107392
Novel substrate of ABCG2
More description
DCC3733 Nsc-104999
Ligand of the Grb7 SH2 domain, inhibiting the growth of MDA-MB-468 cancer cells
More description
DCC3732 Nsc103054
Novel inhibitor of ABCG2 transporter function
More description
DCC3731 Nsc1011
Ras converting enzyme 1 (Rce1) inhibitor
More description
DCC3730 Nsc-100874
Novel antagonist of the Grb7 SH2 domain; Antitumor Agent
More description
DCC3729 Nsc1008
Novel Inhibitor of the Ras Converting Enzyme 1 (Rce1) Protease, Disrupting Ras Membrane Localization in Human Cells
More description
DCC3728 Nsc10010
Novel potent growth inhibitor for gammaherpesvirus-associated B-lymphomas through activation of both the NF-κB and c-Myc-mediated signaling pathways
More description
DCC3727 Ns-6784 Hydrochloride
Novel α7 nAChR agonist at human and rat receptors
More description
DCC3726 Ns-6740
Novel potent α7 nAChR partial agonist
More description
DCC3725 Ns4591
Novel molulator of SK-IK channels [small- and intermediate-conductance Ca2(+) -activated K(+) channels]
More description
DCC3724 ns3-in-5
Novel allosteric inhibitor of HCV NS3 protein function
More description
DCC3723 ns3/4a-in-12
Novel Inhibitor with Activity against NS3/4A proteases from Multiple Hepatitis C Virus Genotypes
More description
DCC3722 Ns-2710
Potent, non-selective partial agonist at GABAA receptors with little efficacy at the alpha1 subtype and more at alpha2 and alpha3
More description
DCC3721 Ns-0011
Novel inhibitor of CDK5 translocation, increasing CDK5 accumulation in the nucleus, suppressing both cancer cell proliferation and xenograft tumorigenesis.
More description
DCC3719 Nrf2/ho-1 Activator Ll202
Novel activator of the Nrf2/HO-1 pathway, upregulating heme oxygenase-1 (HO-1) via promoting nuclear translocation of nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) to regulate LPS‐induced oxidative stress in macrophages
More description
DCC3718 Nr2b-in-1
Novel NMDA/NR2B Antagonist
More description
DCC3717 Nqo1 Substrate 1
Novel substrate for NAD(P)H: quinone oxidoreductase 1 (NQO1), acting as an effective intracellular ROS generator for the treatment of drug-resistant non-small-cell lung cancer
More description
DCC3716 Nps-89636
Calcilytic negative allosteric modulator of calcium-sensing receptor (CaR)
More description
DCC3715 Npr-c Activator 1
Novel potent activator of the natriuretic peptide receptor C (NPR-C) with EC 50 ~1 μM
More description
DCC3714 Nplc0393
Novel inhibitor of TGF-β1 signaling pathway, inhibiting the upregulation of MAT2A mechanistically, dose-dependently activating PP2Cα and efficiently alleviating liver fibrosis
More description
DCC3713 Npd9055
Novel heterotrimeric G-protein Gi modulator, inhibiting GDP/GTP exchange on a Gαi subunit induced by a G-protein-coupled receptor agonist, but not on another G-protein from the Gαs family, regulating Gβγ-dependent cellular processes, most likely by causin
More description
DCC3712 Npd8617
Novel tubulin inhibitor
More description
DCC3711 Npd7155
Novel competitive MTH1 inhibitor
More description

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X